SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members express bullish sentiment and anticipate a breakout, particularly around the $200 mark. Discussions also involve various Solana-based meme coins like $WAGMI and $SOLYCAT, reflecting interest in the Solana ecosystem. Some traders are eyeing potential short squeezes and retesting of resistance levels.

Trump For President

TRUMP CRYPTO is seeing active discussion driven by community speculation on its long-term potential and mentions of potential partnerships. While some investors express bullish sentiment and compare it to other meme coins, others criticize it as a "scam coin" and point to its significant price decline since inception. The coin is also being discussed in the context of broader political opinions and the performance of other Trump-related assets.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid buyout speculation, particularly involving Novartis, following reports of a potential acquisition approach. The community is actively discussing the possibility of a deal, with some anticipating a significant premium, while others focus on upcoming data readouts and analyst target bumps. The company's strong uptrend after trial optimism and consistent institutional interest are also key talking points.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is gaining attention, particularly within the Phantom Wallet community, as traders discuss its potential for a breakout. Bullish sentiment is fueled by perceived positive chart patterns and strong momentum, with many highlighting its potential for rapid gains. The crypto is currently testing resistance levels, leading to increased monitoring of volume.

Pump.fun

$PUMP is gaining traction, with community members actively discussing its potential and close ties to the Pump.fun platform on the Solana blockchain. Bullish sentiment is fueled by the "We're All Gonna Make It" ($WAGMI) mentality, and references to a strong community that supports the project. Some community members are drawing comparisons to other popular decentralized exchanges, hoping for a similar trajectory.

CryingNTheCasino

CryingNTheCasino ($TEARY) is trending due to its focus on community building and a strong 'HODL' mentality, with the community emphasizing its power and shared belief in the project. The project's development team is comprised of OGs, which is contributing to positive sentiment.

Just a dead guy

DEADGUY, a meme coin, is gaining traction as community members highlight its potential for a 'stealth relaunch' and are actively sharing the contract address. The coin's rising holder count and perceived strong community energy are key discussion points. Some are drawing comparisons to other meme coins, speculating on significant market cap growth.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community rallies around the revival of OG memes and a return to the culture's roots. Community members express excitement and a shared belief in the project, emphasizing its strong community and organic growth. The broader discussion revolves around making memes great again and the power of community-driven projects.

WorldFinancial

WorldFinancial ($WLFI) is trending as the community discusses its potential link to Donald Trump and related ventures. Some speculate on partnerships and tokenizing real-world assets, while others voice concerns about centralization and potential for scams. Bullish sentiment clashes with skepticism, leading to active debate around its long-term viability.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

Novartis is trending due to positive developments and strategic moves, including strong Phase III results for Fabhalta in kidney disease, setting the stage for potential FDA approval, and promising data for Scemblix in leukemia. The community is discussing Novartis' potential growth strategy and pipeline, as well as potential acquisitions and partnerships in the radiopharmaceutical and AI spaces. Analysts note the company's solid financials and key catalysts, although some express concerns about Cosentyx and future earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Equity

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

Shares of Lyra Therapeutics, Inc. (LYRA) rocketed 370% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-reports-positive-results-enlighten-2-phase-3">announced</a> positive results from its late-stage clinical trial of LYR-210 in adult patients with chronic rhinosinusitis.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention.It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat CRS.LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial, the company said.The trial enrolled approximately 180 CRS patients who had not had prior ethmoid sinus surgery. While some received the company’s lead product, others received a sham control.The implant was well-tolerated, and most commonly reported adverse events included epistaxis, upper respiratory tract infection, chronic sinusitis, acute sinusitis, nasopharyngitis, COVID-19, and headache, the company added.Lyra said that its therapy is expected to help the estimated four million CRS patients in the United States who fail medical management each year.Lyra CEO Maria Palasis stated that the company now plans to align with the FDA on the path forward for submitting a new drug application.The company had previously conducted a late-stage study for the implant, which did not meet its goals.On Stocktwits, retail sentiment around Lyra jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_2_05_49_PM_png_c936942df7.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="62"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> is up by about 116% this year and by about 43% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-and-microsoft-team-up-to-simplify-cyber-threat-intelligence/chkYeQARbH1">CrowdStrike And Microsoft Team Up To Simplify Cyber Threat Intelligence: Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled

LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24. 

Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for LYRA
 DateFirmActionFromTo May 2020B of A SecuritiesInitiates Coverage OnBuy May 2020JefferiesInitiates Coverage OnBuy
 View More Analyst Ratings for LYRA

 View the...

Why Lyra Therapeutics Stock Is Down 93% Today

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
read more...

The volume for Lyra Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 516% of the 65-Day Volume Moving Average

LYRA's total volume now sits at 2M. The +0.16% price change was insignificant, leaving IBM's price at $6.23...

Lyra Therapeutics (LYRA, $6.13) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024

This indicator may be signaling that LYRA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Lyra Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$5.26	--	--	N/A
Q2 '25	-$5.53	-$5.51	0.30%	BEAT
Q1 '25	-$0.15	-$6.50	-4233.33%	MISSED
Q4 '24	-$0.12	-$0.16	-33.33%	MISSED
Q3 '24	-$0.22	-$0.18	16.28%	BEAT

LYRA
Lyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest LYRA News

LYRALyra Therapeutics Inc